Predict your next investment

HEALTHCARE | Drug Development
skbp.com

See what CB Insights has to offer

Founded Year

1993

Stage

IPO | IPO

Total Raised

$100M

Date of IPO

7/2/2020

Market Cap

8849.40B

About SK Biopharmaceuticals

SK Biopharmaceuticals (KRX: 326030), part of SK Group, is focused on the research and development of treatments for disorders of the central nervous system (CNS) and cancer. SK Biopharmaceuticals has a pipeline of compounds in development for the treatment of CNS disorders including epilepsy, sleep disorder, and attention deficit hyperactivity disorder, among others.

SK Biopharmaceuticals Headquarter Location

221, Pangyoyeok-ro, Bundang-gu

Seongnam, 13494,

South Korea

+82-31-8093-0114

Latest SK Biopharmaceuticals News

SK Biopharm’s new drugs meet hopeful response, eyes $864mn in sales from epilepsy drug2021.09.07 13:36

Sep 7, 2021

SK Biopharm’s new drugs meet hopeful response, eyes $864mn in sales from epilepsy drug 2021.09.07 13:36:58 | 2021.09.07 13:47:24 Receiver SK Biopharmaceuticals’ novel drugs including epilepsy drug Xcopri (cenobamate) are gearing up for aggressive global expansion after their initial launches in key pharmaceutical markets North America and Europe have drawn favorable responses. According to sources on Monday, the Korean pharmaceutical company kicked off Phase 1 trials in the U.S. and Hungary to evaluate cenobamate currently indicated for adults in children and adolescents with partial seizures. Cenobamate was approved for the treatment of partial-onset seizures in adults in the U.S. in November 2019 and in Europe in March 2021. Cenobamate sales in the U.S., the world’s biggest pharmaceutical market, have been growing fast since its launch with its second-quarter sales reaching 18 billion won ($15.6 million). The number of prescriptions jumped by 38 percent on quarter to 20,445 cases. SK Biopharmaceuticals has succeeded in expanding cenobamate sales in the U.S. despite Covid-19 restrictions at hospitals thanks to its aggressive digital-based promotions, the company said. Photo provided by SK Biopharmaceuticals Co. Market analysts project that cenobamate-related sales would hit 1 trillion won within seven years after exceeding 500 billion won in five years given the pace in market expansion and new clinical trials for additional indications. The company has been eagerly exploring European markets to sell the drug. The company’s European partner Angelini Pharma launched cenobamate in Germany in June. Angelini Pharma plans to sell the drug across 41 European countries in the future. SK Biopharmaceuticals received about 123.5 billion won in milestone payments from the Italy-based partner in March when marketing approval was granted in Europe. SK Biopharmaceuticals’ narcolepsy drug Sunosi (solriamfetol) is also on track for marketing in broader global markets. Jazz Pharmaceuticals, the marketing authorization holder of the drug, recently started selling the drug in Canada following its launches in the US., Germany, Denmark, France and Italy. Sunosi sales in the second quarter amounted to $12.1 million, and its sales are expected to surge upon its launch in Canada. SK Biopharmaceuticals’ new pipelines treatment on rare childhood epilepsy and refractory/metastatic tumors. In July, SK Biopharmaceuticals said it aims to grow into one of the top 10 global healthcare companies by 2030. By Park Yoon-gyun and Minu Kim [ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved] 10 TUE

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SK Biopharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SK Biopharmaceuticals is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

S

Sleep Health & Wellness

792 items

These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

SK Biopharmaceuticals Patents

SK Biopharmaceuticals has filed 117 patents.

The 3 most popular patent topics include:

  • Amines
  • Psychiatric diagnosis
  • Stimulants
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/13/2018

9/14/2021

Piperazines, Psychiatric diagnosis, Atypical antipsychotics, Piperidines, Fluoroarenes

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/13/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/14/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Piperazines, Psychiatric diagnosis, Atypical antipsychotics, Piperidines, Fluoroarenes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

SK Biopharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SK Biopharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.